By Fineline Cube Shanghai ZJ Bio-Tech Co., Ltd. (SHA: 688317) announced that its Ebola Virus Nucleic Acid Detection Kit (Fluorescence PCR) has been granted inclusion in the World Health Organization (WHO) Emergency Use Listing (EUL), specifically validated for detection of the Bundibugyo ebolavirus strain, enabling global procurement for outbreak response.
Regulatory Milestone & Product Specifications
| Component | Detail |
|---|---|
| Company | Shanghai ZJ Bio-Tech Co., Ltd. (SHA: 688317) |
| Product | Ebola Virus Nucleic Acid Detection Kit (Fluorescence PCR) |
| Regulatory Achievement | WHO Emergency Use Listing (EUL) |
| Target Pathogen | Bundibugyo ebolavirus (one of six known Ebola virus species) |
| Technology Platform | Real-time fluorescence PCR (polymerase chain reaction) |
| Listing Duration | One year (standard EUL validity period unless exceptional circumstances arise) |
| Procurement Eligibility | Immediate eligibility for UN agencies and international organizations |
Strategic Significance & Global Health Impact
- Outbreak Response Capability: Enables rapid deployment of diagnostic testing during Ebola outbreaks, critical for early case identification and containment
- Strain-Specific Detection: Bundibugyo ebolavirus has caused multiple outbreaks in Uganda and Democratic Republic of Congo, with case fatality rates ranging from 25-40%
- Chinese Diagnostic Leadership: Represents continued expansion of Chinese in vitro diagnostic (IVD) companies into global infectious disease surveillance and response markets
- Emergency Preparedness: Strengthens global health security infrastructure by diversifying supply sources for critical Ebola diagnostics
Market Context & Competitive Positioning
| Market Factor | Implication |
|---|---|
| Global Ebola Diagnostics Market | Estimated at $85 million annually, highly dependent on outbreak frequency and geographic distribution |
| WHO EUL Requirements | Stringent analytical and clinical validation requirements ensure high-quality, reliable diagnostic performance |
| Competitive Landscape | Limited number of WHO-approved Ebola diagnostics; primarily supplied by European and North American manufacturers |
| ZJ Bio-Tech Advantage | Cost-competitive manufacturing scale; established track record in molecular diagnostics for emerging pathogens |
Shanghai ZJ Bio-Tech, a publicly traded Chinese IVD company specializing in molecular diagnostic reagents and instruments, has previously received WHO prequalification for other infectious disease tests, including tuberculosis and HIV viral load assays, demonstrating consistent quality standards meeting international regulatory requirements.
Procurement & Implementation Framework
- Primary Buyers: World Health Organization, UNICEF, Médecins Sans Frontières (MSF), and national public health agencies in Ebola-endemic regions
- Distribution Channels: Through established emergency response supply chains and regional reference laboratories
- Training & Support: Comprehensive technical documentation and training materials provided as part of WHO EUL requirements
- Quality Assurance: Ongoing batch release testing and post-market surveillance to maintain EUL status
Forward‑Looking Statements
This brief contains forward-looking statements regarding Shanghai ZJ Bio-Tech’s WHO EUL listing, procurement expectations, and market opportunities. Actual results may differ due to risks including outbreak occurrence patterns, competitive dynamics, regulatory compliance maintenance, and geopolitical factors affecting international procurement decisions.-Fineline Info & Tech